What types of cancer is larotrectinib used to treat?

Larotrectinib is a highly selective TRK inhibitor mainly used to treat patients with solid tumors with NTRK gene fusion. Different from traditional treatment methods that classify cancers based on their location, larotrectinib provides precise treatment based on the genetic characteristics of the tumor. Regardless of whether the cancer originates from the lung, thyroid, liver, or other organs, as long as the NTRK gene fusion is detected, it is possible to benefit from larotrectinib treatment. This mechanism makes larotrectinib one of the first "tissue-independent" cancer treatments.

In clinical applications, larotrectinib has been widely used in the treatment of a variety of solid tumors, including soft tissue sarcomas in adults and children, thyroid cancer, non-small cell lung cancer, breast cancer, colorectal cancer, and certain types of pediatric fibrosarcomas. Although these tumor types have different origins, their common molecular feature is the presence of NTRK1, NTRK2 or NTRK3 NTRK3 gene fusions, which make them respond well to TRK inhibitors. Multiple clinical studies have shown that the overall response rate (ORR) of larotrectinib in these patients exceeds 70% and the therapeutic effect is significant.

In addition to common solid tumors, larotrectinib also shows good therapeutic potential for some rare cancers. For example, some rare patients with NTRK fusion-positive salivary gland cancer, pancreatic cancer, biliary tract cancer, and brain glioma may also be considered for treatment with larotrectinib. Since traditional treatments often have limited effects on these patients, larotrectinib provides a new treatment direction and improves overall survival rate and quality of life.

It should be noted that the indications for larotrectinib strictly depend on the results of genetic testing. Not all cancer patients are suitable for larotrectinib treatment, so NTRK gene fusion testing must be performed before treatment, and the corresponding treatment plan can be formulated only after the positive result is confirmed. At the same time, during treatment, doctors also need to monitor the efficacy and adverse reactions based on the patient's specific condition to ensure the safety and continuity of treatment.

Reference materials:https://www.vitrakvi.com/